IL271849A - Targeting chromosomal instability and downstream cytosolic DNA signaling for cancer therapy - Google Patents

Targeting chromosomal instability and downstream cytosolic DNA signaling for cancer therapy

Info

Publication number
IL271849A
IL271849A IL271849A IL27184920A IL271849A IL 271849 A IL271849 A IL 271849A IL 271849 A IL271849 A IL 271849A IL 27184920 A IL27184920 A IL 27184920A IL 271849 A IL271849 A IL 271849A
Authority
IL
Israel
Prior art keywords
cancer treatment
chromosomal instability
cytosolic dna
dna signaling
downstream
Prior art date
Application number
IL271849A
Other languages
English (en)
Hebrew (he)
Original Assignee
Memorial Sloan Kettering Cancer Center
Univ Cornell
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center, Univ Cornell filed Critical Memorial Sloan Kettering Cancer Center
Publication of IL271849A publication Critical patent/IL271849A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/04Nitro compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/118Prognosis of disease development
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/136Screening for pharmacological compounds
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
IL271849A 2017-07-10 2020-01-06 Targeting chromosomal instability and downstream cytosolic DNA signaling for cancer therapy IL271849A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762530661P 2017-07-10 2017-07-10
PCT/US2018/041480 WO2019014246A1 (en) 2017-07-10 2018-07-10 TARGETING CHROMOSOMIC INSTABILITY AND SIGNALING OF CYTOSOLIC DNA IN AVAL FOR THE TREATMENT OF CANCER

Publications (1)

Publication Number Publication Date
IL271849A true IL271849A (en) 2020-02-27

Family

ID=63036469

Family Applications (1)

Application Number Title Priority Date Filing Date
IL271849A IL271849A (en) 2017-07-10 2020-01-06 Targeting chromosomal instability and downstream cytosolic DNA signaling for cancer therapy

Country Status (12)

Country Link
US (2) US11821042B2 (https=)
EP (1) EP3652349A1 (https=)
JP (1) JP7197556B2 (https=)
KR (1) KR20200037796A (https=)
CN (1) CN111295454A (https=)
AU (1) AU2018300007A1 (https=)
BR (1) BR112020000477A2 (https=)
CA (1) CA3069515A1 (https=)
IL (1) IL271849A (https=)
MX (1) MX2020000406A (https=)
SG (1) SG11202000132WA (https=)
WO (1) WO2019014246A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018045155A1 (en) * 2016-09-02 2018-03-08 The Board Of Trustees Of The University Of Illinois Kif13b-derived peptide and method of inhibiting angiogenesis
AU2018300007A1 (en) 2017-07-10 2020-02-27 Cornell University Targeting chromosomal instability and downstream cytosolic DNA signaling for cancer treatment
JP7226763B2 (ja) * 2017-08-17 2023-02-21 国立大学法人山口大学 癌幹細胞における薬物耐性の低減剤、癌幹細胞における転移能の抑制剤及び癌の転移性再発リスクを予測する方法
CN114761804A (zh) * 2019-06-21 2022-07-15 艾福姆德尤股份有限公司 治疗癌症的方法
US20230346785A1 (en) * 2020-02-19 2023-11-02 Ibmc - Instituto De Biologia Molecular E Celular 4-PYRROLIDIN-1-Yl-5-P-TOLYL-THIENO[2,3-D] PYRIMIDINE FOR USE IN THE TREATMENT OF AGING-ASSOCIATED AND PREMATURE AGING DISEASES THROUGH RESTORED CHROMOSOMAL STABILITY AND INHIBITION OF CELLULAR SENESCENCE
JP2023534375A (ja) * 2020-05-28 2023-08-09 王 道祥 細胞病理学的サンプルに対する多重染色切片調製法
AU2021336887A1 (en) * 2020-09-02 2023-03-30 Memorial Sloan Kettering Cancer Center Methods and compositions for targeting cytosolic dsDNA signaling in chromosomally unstable cancers
US20240207248A1 (en) * 2021-04-23 2024-06-27 Baruch S. Blumberg Institute Methods, kits and compositions for reducing chromosomal instability in cancer cells
CN113341154B (zh) * 2021-05-14 2024-11-05 医工瑞思(福建)工程研究中心有限公司 一种检测血栓或凝血相关疾病的生物标志物及其应用
IL310863A (en) 2021-08-26 2024-04-01 Volastra Therapeutics Inc Spiro indoline inhibitors of kif18a
CN115354078B (zh) * 2022-09-02 2023-07-07 中山大学附属第一医院 骨肉瘤检测标记物及其应用
EP4488389A1 (en) * 2023-07-05 2025-01-08 Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P. CNIO) Signature for the prognosis of brain metastasis relapse

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4962091A (en) 1986-05-23 1990-10-09 Syntex (U.S.A.) Inc. Controlled release of macromolecular polypeptides
WO1994007529A1 (en) 1992-09-25 1994-04-14 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6306434B1 (en) 1997-02-12 2001-10-23 Chong Kun Dang Corp. Pharmaceutical composition comprising cyclosporin solid-state microemulsion
GB201121070D0 (en) 2011-12-07 2012-01-18 Isis Innovation composition for delivery of biotherapeutics
EP2934598B1 (en) 2012-12-19 2018-04-18 Board Of Regents, The University Of Texas System Pharmaceutical targeting of a mammalian cyclic di-nucleotide signaling pathway
WO2015036643A2 (es) 2013-09-13 2015-03-19 Sierra Jiménez Angels Marcador para predecir metástasis del cancer de mama
BR112016020897A2 (en) * 2014-03-11 2018-01-23 The Council Of The Queensland Institute Of Medical Research Determination of cancer aggressiveness, prognosis, and responsiveness to treatment
JP6898848B2 (ja) * 2014-09-19 2021-07-07 メモリアル スローン ケタリング キャンサー センター 脳転移を治療するための方法
WO2016176222A1 (en) 2015-04-30 2016-11-03 University Of Washington Cgas in systemic lupus erythematosus (sle)
AU2018300007A1 (en) 2017-07-10 2020-02-27 Cornell University Targeting chromosomal instability and downstream cytosolic DNA signaling for cancer treatment

Also Published As

Publication number Publication date
SG11202000132WA (en) 2020-02-27
CA3069515A1 (en) 2019-01-17
US11821042B2 (en) 2023-11-21
MX2020000406A (es) 2020-10-01
US20240110246A1 (en) 2024-04-04
WO2019014246A1 (en) 2019-01-17
AU2018300007A1 (en) 2020-02-27
EP3652349A1 (en) 2020-05-20
JP7197556B2 (ja) 2022-12-27
BR112020000477A2 (pt) 2020-07-21
US20210130903A1 (en) 2021-05-06
KR20200037796A (ko) 2020-04-09
CN111295454A (zh) 2020-06-16
JP2020526206A (ja) 2020-08-31

Similar Documents

Publication Publication Date Title
IL271849A (en) Targeting chromosomal instability and downstream cytosolic DNA signaling for cancer therapy
IL290695A (en) Combined immunotherapy and cytokine control therapy for cancer treatment
IL290149A (en) Combined treatment for cancer
IL271946A (en) Combination for cancer treatment
IL259017A (en) Cancer cure is intended
IL256790B (en) Axl-specific antibody-drug conjugates for cancer treatment
SG10201913631TA (en) Rna for cancer therapy
LT3423087T (lt) Kompleksinė priešvėžinė terapija
PT3576740T (pt) Tratamento de cancro
IL268463A (en) Cancer treatment
IL310084B2 (en) Integrated and focused treatment
GB201706451D0 (en) Cancer treatment
ZA201904736B (en) Targeted doxorubicin-gold nanoconjugates for tumor therapy
IL274626A (en) Cancer treatment
SG11202001796SA (en) Bacteria for targeting tumors and treating cancer
ZA201802618B (en) Anti-cd43 antibody and use thereof for cancer treatment
SG11201605745VA (en) Targeting clptm1l for treatment and prevention of cancer
MX2016012244A (es) Compuestos y sus metodos de uso.
IL248328A0 (en) Bracelets for the administration of drugs for the treatment of resistant cancer and for the use of combined therapy
SG11201702260RA (en) Anti-cancer agent and cancer cell killing method
IL255541A (en) Cabazitaxel and its use for treating cancer
GB201704909D0 (en) Cancer therapy
HK40029865A (en) Targeting chromosomal instability and downstream cytosolic dna signaling for cancer treatment
GB201711855D0 (en) Cancer therapy
IL274866A (en) Preparations and methods for the treatment of cancer